Scot Ebbinghaus, MD
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of pembrolizumab (Keytruda) in combination with axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma (RCC).
The FDA approved the pembrolizumab/axitinib combination in April 2019 for use in this setting.
Powles T, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib vs sunitinib as first-line therapy for advanced renal cell carcinoma: KEYNOTE-426. J Clin Oncol. 2019;37(suppl 15; abstr 543) doi: 10.1200/JCO.2019.37.7_suppl.543.
... to read the full story